Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  Mesoblast limited    MSB   AU000000MSB8

MESOBLAST LIMITED (MSB)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Securities Exc…
09/12/2018 09/13/2018 09/14/2018 09/17/2018 09/18/2018 Date
1.645(c) 1.635(c) 1.68(c) 1.7(c) 1.655 Last
1 014 111 172 941 958 588 701 754 731 363 Volume
+1.23% -0.61% +2.75% +1.19% -2.65% Change
More quotes
Financials (AUD)
Sales 2019 27,4 M
EBIT 2019 -101 M
Net income 2019 -108 M
Debt 2019 -
Yield 2019 -
Sales 2020 120 M
EBIT 2020 -6,51 M
Net income 2020 39,7 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020 24,69
Capi. / Sales2019 29,9x
Capi. / Sales2020 6,83x
Capitalization 817 M
More Financials
Company
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform.Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory... 
More about the company
Surperformance© ratings of Mesoblast limited
Trading Rating : - Investor Rating :
More Ratings
Latest news on MESOBLAST LIMITED
12:48pMESOBLAST : Tasly Pharmaceutical Group Receives All Necessary Approvals for Tran..
AQ
09/17Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction W..
GL
08/30Mesoblast Reports Fourth Quarter and Full-Year 2018 Financial Results and Ope..
GL
08/29Mesoblast Provides Update on Transaction With Tasly Pharmaceutical Group
GL
08/28MESOBLAST : Financial Results Webcast for 2018 Financial Year
AQ
07/17Mesoblast Enters Into Strategic Cardiovascular Alliance for China With Tasly ..
GL
07/11Leading Commercial and Transactional Healthcare Executive Shawn Cline Tomasel..
GL
07/03MESOBLAST : Enters Into US$50M Financing with Novaquest Capital for Commercial R..
AQ
07/02MESOBLAST : Enters Into US$50M Financing with Novaquest Capital for Commercial R..
AQ
06/21Key Day 100 Survival Outcomes of Phase 3 Trial for Acute Graft Versus Host Di..
GL
More news
Sector news : Biotechnology & Medical Research - NEC
07:35aREGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans -- U..
DJ
09/13Roche steps up efficiency drive to take sting out of biosimilars
RE
09/12EUROPE : European stocks shrug off trade worries as oil stocks rally
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
09/17Tasly Pharmaceutical receives all necessary approvals for transaction with Me.. 
09/17Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction W.. 
09/16Head-To-Head Survey: Autolus Therapeutics $AUTL and Mesoblast $MESO  
09/14-$0.24 Earnings Per Share Expected for Mesoblast limited $MESO This Quarter  
09/13Comparing Autolus Therapeutics $AUTL and Mesoblast $MESO  
More tweets
Qtime:15
News from SeekingAlpha
09/17Tasly Pharmaceutical receives all necessary approvals for transaction with Me.. 
09/03MESOBLAST'S TRIAL DATA IN AGVHD : An IOMachine Runthrough 
08/30Mesoblast misses on revenue 
08/29Mesoblast (MESO) CEO Dr. Silviu Itescu on Q4 2018 Results - Earnings Call Tra.. 
08/29Mesoblast provides update on transaction with Tasly Pharmaceutical Group 
Chart MESOBLAST LIMITED
Duration : Period :
Mesoblast limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MESOBLAST LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 3,95  AUD
Spread / Average Target 133%
EPS Revisions
Managers
NameTitle
Silviu Itescu Chief Executive Officer, MD & Executive Director
Brian Jamieson Non-Executive Chairman
Joshua Muntner Chief Financial Officer
Donna L. Skerrett Chief Medical Officer
Michael Robert Spooner Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
MESOBLAST LIMITED16.44%588
CELLTRION, INC.--.--%33 722
IQVIA HOLDINGS INC27.75%25 338
LONZA GROUP20.13%24 487
INCYTE CORPORATION-28.11%14 247
SEATTLE GENETICS, INC.46.09%12 094